Alps Group Inc is a MY-based company operating in Biotechnology industry. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
GLLIU stock price ended at $3.05 on 木曜日, after dropping 8.96%
On the latest trading day Oct 30, 2025, the stock price of GLLIU fell by 8.96%, dropping from $4.20 to $3.05. During the session, the stock saw a volatility of 37.70%, with prices oscillating between a daily low of $3.05 and a high of $4.20. On the latest trading day, the trading volume for GLLIU rose by 500 shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 600 shares were traded, with a market value of approximately $507.5M.